Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000240973 | SCV000300757 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Labcorp Genetics |
RCV000199893 | SCV000255252 | pathogenic | Hereditary breast ovarian cancer syndrome | 2022-08-20 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 216855). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Phe1506Thrfs*4) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). |
Ambry Genetics | RCV000575412 | SCV000668824 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-04-11 | criteria provided, single submitter | clinical testing | The c.4515_4525del11 pathogenic mutation, located in coding exon 10 of the BRCA2 gene, results from a deletion of 11 nucleotides at nucleotide positions 4515 to 4525, causing a translational frameshift with a predicted alternate stop codon (p.F1506Tfs*4). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Laboratory of Medical Genetics, |
RCV001729453 | SCV001976827 | pathogenic | Fanconi anemia complementation group D1 | 2021-10-05 | criteria provided, single submitter | clinical testing | PVS1, PM2, PP5 |
Baylor Genetics | RCV003474965 | SCV004212902 | pathogenic | Familial cancer of breast | 2021-09-24 | criteria provided, single submitter | clinical testing |